Each softgel capsule contains Alfacalcidol 0.25 micrograms.
Alfacalcidol or 1-α-hydroxyvitamin D3 is one of vitamin D analogue. Alfacalcidol is rapidly converted in liver to 1,25-dihydroxyvitamin D3 {1,25-(OH)2D3}, the metabolite of vitamin D3 which acts as a regulator of calcium and phosphate metabolism.
Impaired endogenous production of 1,25-dihydroxyvitamin D3 by the kidneys appears to contribute to the disturbances in mineral metabolism found in several disorders, including renal bone disease, hypoparathyroidism and vitamin D-dependent rickets. These disorders require high doses of vitamin D for their correction.
Osteoporosis.
Renal osteodystrophy.
Hypoparathyroidism.
Hyperparathyroidism with bone disease.
Nutritional and malabsorptive rickets and osteomalacia.
Hypophosphatemic vitamin D-resistant rickets and osteomalacia.
Initial dose: Adults & children >20 kg body weight: 0.5-1 μg/day.
<20 kg body weight: 0.05 μg/kg/day.
The dosage of Medi-α 0.25 should be adjusted thereafter to avoid hypercalcemia according to the biochemical response.
Hypercalcemia, Hypermagnesemia.
Hypersensitivity to Vitamin D or its analogues.
If the patient is pregnant or breastfeeding, inform the physician prior to the commencement of therapy with this medicine.
Store in a dry place below 25°C for Alu-Alu blister and below 30°C for PVC/PVDC-Alu blister.
A11CC03 - alfacalcidol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
Medi-α soft-gelatin cap 0.25 mcg
6 × 10's
Medi-α soft-gelatin cap 0.5 mcg
3 × 10's
Sign Out
